Bristol-Myers Squibb and Samsung BioLogics Expand Manufacturing Agreement
PTSM: Pharmaceutical Technology Sourcing and Management
Bristol-Myers Squibb and Samsung BioLogics expand their manufacturing agreement to cover biologic medicines.
Bristol-Myers Squibb and Samsung BioLogics have expanded their existing manufacturing agreement, in which Samsung will manufacture commercial drug substances and drug product for several Bristol-Myers Squibb biologic medicines at Samsung's Incheon, China manufacturing site. Financial terms of the agreement are not disclosed.
Bristol-Myers Squibb and Samsung announced their first manufacturing agreement in July 2013 to collaborate in the production of a single commercial antibody cancer drug substance.
Source: Bristol-Myers Squibb
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
